よむ、つかう、まなぶ。
資料１－３ 指摘事項に対する回答 (18 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_35961.html |
| 出典情報 | 先進医療会議 先進医療技術審査部会（第155回 11／9）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clin Cancer Res. 27(10): 2723-2733, 2021
・ Ito T, Ishigami M, Yamamoto T, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H,
Yasuda S, Toyoda H, Yokota K, Hase T, Nishio N, Maeda O, Kato M, Hashimoto N, Hibi H, Kodera Y,
Sone M, Ando Y, Akiyama M, Shimoyama Y, Fujishiro M. Clinical course of liver injury induced by
immune checkpoint inhibitors in patients with advanced malignancies. Hepatol Int. 15(5): 1278-1287,
2021
・ Kanda M, Shimizu D, Miyata K, Maeda O, Tanaka C, Inokawa Y, Hattori N, Hayashi M, Ando M,
Kuwatsuka Y, Murotani K, Nakayama G, Koike M, Ando Y, Ebata T, Kodera Y. Neoadjuvant docetaxel,
oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study
protocol of an open-label phase II trial. Contemp Clin Trials Commun. 24: 100853, 2021
・ Minami H, Ando Y, Tamura K, Tajima T, Isaacs R. Phase I Study of LFA102 in Patients With Advanced
Breast Cancer or Castration-resistant Prostate Cancer. Anticancer Res. 40(9): 5229-5235, 2020
・ Takano N, Yamada S, Hirakawa A, Yokoyama Y, Kawashima H, Maeda O, Okada T, Ohno E,
Yamaguchi J, Ishikawa T, Sonohara F, Suenaga M, Takami H, Hayashi M, Niwa Y, Hirooka Y, Ito Y,
Naganawa S, Ando Y, Nagino M, Goto H, Fujii T, Kodera Y. Phase II study of chemoradiotherapy
combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal
adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study. Nagoya J Med Sci,
81: 233-239, 2019
・ Ando Y, Iwasa S, Takahashi S, Saka H, Kakizume T, Natsume K, Suenaga N, Quadt C, Yamada Y. Phase
I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid
tumors.Cancer Sci. 110(3): 1021-1031, 2019
・ Ishikawa T, Kawashima H, Ohno E, Matsubara H, Sasaki Y, Achiwa K, Kanamori A, Sumi H, Hirai T,
Nonogaki K, Tsuzuki T, Kuroiwa M, Hattori M, Maruta S, Hiramatsu T, Ando M, Hashimoto S, Hirooka
Y.
Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as
Second-Line Chemotherapy in Advanced Pancreatic Cancer. Oncology. 96: 1-7, 2019
・ Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A,
Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M. Correction to: Phase II study of
sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic
neuroendocrine tumor. Invest New Drugs. 37(3): 591, 2019
・ Hirooka Y, Kasuya H, Ishikawa T, Kawashima H, Ohno E, Villalobos IB, Naoe Y, Ichinose T, Koyama
N, Tanaka M, Kodera Y, Goto H. A Phase I clinical trial of EUS-guided intratumoral injection of the
oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer. 18: 596, 2018
・ Yamada S, Fujii T, Yokoyama Y, Kawashima H, Maeda O, Suzuki K, Okada T, Ono E, Yamaguchi J,
Takano N, Takami H, Hayashi M, Niwa Y, Hirooka Y, Ito Y, Naganawa S, Ando Y, Nagino M, Goto H,
Kodera Y. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable
locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 81: 815-821, 2018
・ Yonemori K, Kodaira M, Satoh T, Kudo T, Takahashi S, Nakano K, Ando Y, Shimokata T, Mori J, Inoue
K, Oakley GJ, Sakaguchi S, Tamura K. A phase 1 study of olaratumab plus doxorubicin in Japanese
patients with advanced soft-tissue sarcoma. Cancer Sci. 109(12): 3962-3970, 2018
7
・ Ito T, Ishigami M, Yamamoto T, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Kawashima H,
Yasuda S, Toyoda H, Yokota K, Hase T, Nishio N, Maeda O, Kato M, Hashimoto N, Hibi H, Kodera Y,
Sone M, Ando Y, Akiyama M, Shimoyama Y, Fujishiro M. Clinical course of liver injury induced by
immune checkpoint inhibitors in patients with advanced malignancies. Hepatol Int. 15(5): 1278-1287,
2021
・ Kanda M, Shimizu D, Miyata K, Maeda O, Tanaka C, Inokawa Y, Hattori N, Hayashi M, Ando M,
Kuwatsuka Y, Murotani K, Nakayama G, Koike M, Ando Y, Ebata T, Kodera Y. Neoadjuvant docetaxel,
oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study
protocol of an open-label phase II trial. Contemp Clin Trials Commun. 24: 100853, 2021
・ Minami H, Ando Y, Tamura K, Tajima T, Isaacs R. Phase I Study of LFA102 in Patients With Advanced
Breast Cancer or Castration-resistant Prostate Cancer. Anticancer Res. 40(9): 5229-5235, 2020
・ Takano N, Yamada S, Hirakawa A, Yokoyama Y, Kawashima H, Maeda O, Okada T, Ohno E,
Yamaguchi J, Ishikawa T, Sonohara F, Suenaga M, Takami H, Hayashi M, Niwa Y, Hirooka Y, Ito Y,
Naganawa S, Ando Y, Nagino M, Goto H, Fujii T, Kodera Y. Phase II study of chemoradiotherapy
combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal
adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study. Nagoya J Med Sci,
81: 233-239, 2019
・ Ando Y, Iwasa S, Takahashi S, Saka H, Kakizume T, Natsume K, Suenaga N, Quadt C, Yamada Y. Phase
I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid
tumors.Cancer Sci. 110(3): 1021-1031, 2019
・ Ishikawa T, Kawashima H, Ohno E, Matsubara H, Sasaki Y, Achiwa K, Kanamori A, Sumi H, Hirai T,
Nonogaki K, Tsuzuki T, Kuroiwa M, Hattori M, Maruta S, Hiramatsu T, Ando M, Hashimoto S, Hirooka
Y.
Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as
Second-Line Chemotherapy in Advanced Pancreatic Cancer. Oncology. 96: 1-7, 2019
・ Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A,
Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M. Correction to: Phase II study of
sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic
neuroendocrine tumor. Invest New Drugs. 37(3): 591, 2019
・ Hirooka Y, Kasuya H, Ishikawa T, Kawashima H, Ohno E, Villalobos IB, Naoe Y, Ichinose T, Koyama
N, Tanaka M, Kodera Y, Goto H. A Phase I clinical trial of EUS-guided intratumoral injection of the
oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer. 18: 596, 2018
・ Yamada S, Fujii T, Yokoyama Y, Kawashima H, Maeda O, Suzuki K, Okada T, Ono E, Yamaguchi J,
Takano N, Takami H, Hayashi M, Niwa Y, Hirooka Y, Ito Y, Naganawa S, Ando Y, Nagino M, Goto H,
Kodera Y. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable
locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 81: 815-821, 2018
・ Yonemori K, Kodaira M, Satoh T, Kudo T, Takahashi S, Nakano K, Ando Y, Shimokata T, Mori J, Inoue
K, Oakley GJ, Sakaguchi S, Tamura K. A phase 1 study of olaratumab plus doxorubicin in Japanese
patients with advanced soft-tissue sarcoma. Cancer Sci. 109(12): 3962-3970, 2018
7